Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs.
We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.
We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.
Location: United States, California, Hayward
Employees: 201-500
Total raised: $177M
Founded date: 2015
Investors 9
Funding Rounds 2
Mentions in press and media 14
| Date | Title | Description |
| 09.03.2021 | Arcus Biosciences Announces New Employment Inducement Grants | HAYWARD, Calif.--(BUSINESS WIRE)--Mar 9, 2021-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Comp... |
| 24.02.2021 | Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights | HAYWARD, Calif.--(BUSINESS WIRE)--Feb 24, 2021-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter an... |
| 28.05.2020 | Gilead enters $2B immuno-oncology deal with Arcus Biosciences | Under the deal, Gilead will pay Arcus $175 million upfront, as well as making a $200 million equity investment and up to $1.6 billion in potential research and development funding, opt-in and milestone payments. Gilead will option programs ... |
| 27.05.2019 | NYSE changes fee schedule in bid to woo biotech companies | “We are providing an improved on-ramp for biotech companies looking to access the public markets and receive the benefits of an NYSE listing, while preserving capital to invest in their businesses,” NYSE COO John Tuttle wrote in an emailed ... |
| 20.02.2018 | Term Sheet — Tuesday, February 20 | IT’S ALL RITE Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop RETAIL WARS: Albertsons strikes again. The national grocery chain announced it will purchase the part of Rite Aid that isn... |
| 13.11.2017 | Arcus Biosciences closes $107M Series C round as industry hunts for blockbuster immunotherapy combinations | Additional therapies are needed to double-down on the tumor and to close any potential escape routes. On Monday, Arcus Biosciences closed a $107 million Series C round for its mission to provide that back-up support. The round was led by GV... |
| 13.11.2017 | Arcus Biosciences Announces $107 Million Series C Financing Led by GV and Initiation of Two Clinical Trials | HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today the completion of a $107 million Series C financing. Th... |
| 05.09.2016 | Arcus Biosciences Raises $70M from GV | Taiho Ventures, LLC today announced its investment in Arcus Biosciences, Inc. of Hayward, California. Arcus raised an additional $70 million in equity capital from Taiho Ventures, GV, Invus, DROIA Oncology Ventures and Stanford University, ... |
| 01.09.2016 | Arcus Biosciences Raises $70M in Series B Funding | Arcus Biosciences, a Hayward, California-based immuno-oncology company, raised an additional $70m in Series B equity funding. Backers included Taiho Ventures, GV, Invus, DROIA Oncology Ventures and Stanford University, and Series A investor... |
| - | Arcus Biosciences Announces New Employment Inducement Grants | HAYWARD, Calif.--(BUSINESS WIRE)--Feb 25, 2021-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Com... |
Show more